Provectus Pharmaceuticals Inc. (PVCT.OB) is a Tennessee-based development stage pharmaceutical company that specializes in oncology and dermatology therapies. Complementing the company’s lineup of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.

In the biotechnology area, the company has developed groundbreaking technology to augment vaccine production and detect viruses. Another area that Provectus is focusing on is the dermatology space. The company is currently conducting Phase 2 clinical trials of their proprietary drug PH-10, to be used as a topical treatment for psoriasis and atopic dermatitis.

Provectus Pharma’s main focus however is in the treatment of cancer. The company is developing advanced therapies to target and destroy the deadliest cancers - melanoma, liver cancer, and breast cancer - while eliminating side effects. Clinical trials for treatment of metastatic melanoma and recurrent breast carcinoma with the company’s PV-10 drug are

Marshall Edwards, a subsidiary of the Australian pharmaceutical company, Novogen Limited, was formed with the specific intent of increasing the focus on an important new oncological discovery known as multiple signal transduction regulators (MSTRs).

Novogen scientists discovered these regulators, and brought Marshall Edwards onboard to develop the products commercially. The main MSTR, called Phenoxodiol, is currently undergoing Phase III clinical testing in the US, Europe, and Australia. The drug is being developed for the treatment of both early and late-stage prostate and cervical cancer, as well as ovarian cancers that have proven to be resistant to chemotherapy.

Phenoxodiol promotes the death of cancer cells by inhibiting harmful proteins which prevent apoptosis (the natural process of self-destruction in certain cells). The drug can be used in conjunction with other, more traditional forms of treatment.

A feeling of cautious excitement comes with every possibility of reducing or eradicating cancerous cells. What sets Marshall